The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Perjeta (Pertuzumab) Market By 2030?
The perjeta (pertuzumab) market has observed swift growth in recent years. Its value is projected to increase from $1.08 million in 2025 to $1.26 million in 2026, at a compound annual growth rate (CAGR) of 15.7%. This expansion in the past can be linked to factors such as the approval of HER2 monoclonal antibodies, a rising occurrence of breast cancer, improvements in HER2 diagnostic methods, impressive clinical trial outcomes, and its inclusion in oncology guidelines.
The market for perjeta (pertuzumab) is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.23 million by 2030, demonstrating a compound annual growth rate (CAGR) of 15.4%. This growth throughout the forecast period can be attributed to several factors, including enhanced identification of HER2-positive patients, broader application in adjuvant therapy contexts, increased uptake of combination treatment regimens, a rise in oncology drug expenditures, and wider global market reach. Key trends expected during the forecast period encompass the broadening of HER2-targeted combination therapies, expanded application in both early and metastatic breast cancer, an increase in the use of dual HER2 blockade strategies, a heightened emphasis on precision oncology, and superior survival outcomes for HER2-positive patients.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp
Which Major Factors Are Contributing To The Development Of The Perjeta (Pertuzumab) Market?
The increasing occurrence of breast cancer is anticipated to boost the expansion of the Perjeta (pertuzumab) market in the future. Breast cancer is defined as a condition where abnormal cells form within the breast tissue, frequently starting in the ducts or lobules. This increase in breast cancer cases stems from shifts in lifestyle, such as higher rates of obesity and inactivity, alongside enhanced early diagnosis facilitated by extensive screening initiatives. Perjeta (pertuzumab) serves as a treatment for HER2-positive breast cancer, functioning by targeting the HER2 receptor; it is commonly administered alongside trastuzumab and chemotherapy to enhance therapeutic results. As an illustration, data from October 2023, provided by Ray of Light Wales, a UK-based non-profit organization, indicates that approximately 600,000 individuals are living in the UK following a breast cancer diagnosis, a figure expected to reach 1.2 million by 2030. Consequently, the growing prevalence of breast cancer is fueling the expansion of the herceptin biosimilars market.
How Does Segment Analysis Break Down The Perjeta (Pertuzumab) Market Structure?
The perjeta (pertuzumab) market covered in this report is segmented –
1) By Source: Human source, Animal source
2) By Product: Monoclonal Antibody, Biologic Drug
3) By Indication: Early Breast Cancer, Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
What Trends Are Shaping The Perjeta (Pertuzumab) Market Structure?
A significant trend in the Perjeta (pertuzumab) market involves concentrating on developing technologically advanced solutions, such as subcutaneous combination therapies, to enhance patient outcomes and improve treatment convenience. These subcutaneous combination therapies refer to methods where two or more drugs are integrated into a single injection administered under the skin to treat a particular condition. For example, in November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, introduced Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment for subcutaneous delivery combines the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, which substantially reduces the time compared to traditional intravenous infusions. Phesgo is indicated for patients with advanced or recurrent HER2-positive colorectal cancer and stands as the first subcutaneous option available for this condition.
Who Are The Major Companies Operating In The Perjeta (Pertuzumab) Market?
Major companies operating in the perjeta (pertuzumab) market are Roche Holding AG
Access The Complete Perjeta (Pertuzumab) Market Report:
https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report
Which Region Stands As The Largest Contributor To The Perjeta (Pertuzumab) Market?
North America was the largest region in the perjeta (pertuzumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model